MA41555A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA41555A
MA41555A MA041555A MA41555A MA41555A MA 41555 A MA41555 A MA 41555A MA 041555 A MA041555 A MA 041555A MA 41555 A MA41555 A MA 41555A MA 41555 A MA41555 A MA 41555A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer treatment
cancer
treatment
Prior art date
Application number
MA041555A
Other languages
English (en)
Inventor
Andrew Fergus
Richard Labotka
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA41555A publication Critical patent/MA41555A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041555A 2015-02-17 2016-02-15 Polythérapie pour le traitement du cancer MA41555A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117283P 2015-02-17 2015-02-17

Publications (1)

Publication Number Publication Date
MA41555A true MA41555A (fr) 2017-12-26

Family

ID=56689146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041555A MA41555A (fr) 2015-02-17 2016-02-15 Polythérapie pour le traitement du cancer

Country Status (8)

Country Link
US (5) US20180235986A1 (fr)
EP (1) EP3258965A4 (fr)
JP (3) JP2018506550A (fr)
CN (1) CN107249635A (fr)
CA (1) CA2976696A1 (fr)
EA (1) EA201791736A1 (fr)
MA (1) MA41555A (fr)
WO (1) WO2016133903A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク,インコーポレーテツド 急性骨髄性白血病の治療のための抗cd38抗体
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (fr) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とcd38阻害剤とを含む医薬組み合わせ物及びその使用方法
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
CN115403603A (zh) 2018-09-14 2022-11-29 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
AU2019362868A1 (en) * 2018-10-17 2021-05-13 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-CD38 antibodies
EP3935087A4 (fr) * 2019-03-08 2022-12-07 Cedars-Sinai Medical Center Agents anti-cd38 pour la désensibilisation et le traitement du rejet médié par anticorps de greffes d'organes
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
EP3980064A1 (fr) 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Polythérapies utilisant des anticorps cd-38
JP7428601B2 (ja) * 2020-06-29 2024-02-06 株式会社神戸製鋼所 ガスシールドアーク溶接方法、構造物の製造方法及びシールドガス
EP4080515A1 (fr) 2021-04-19 2022-10-26 Roche Diagnostics GmbH Procédé de classification d'une étiquette d'identification sur un tube d'échantillon contenant un échantillon et système de laboratoire automatisé

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3312196B1 (fr) * 2005-03-23 2019-07-17 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
MY161991A (en) * 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
CN102961387B (zh) * 2007-08-06 2016-04-27 米伦纽姆医药公司 蛋白酶体抑制剂
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
DK2730581T3 (en) * 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
CN103118706B (zh) * 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2968555T3 (pl) * 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
JP2021059564A (ja) 2021-04-15
US20230201227A1 (en) 2023-06-29
EA201791736A1 (ru) 2017-12-29
US20210369748A1 (en) 2021-12-02
WO2016133903A2 (fr) 2016-08-25
CA2976696A1 (fr) 2016-08-25
EP3258965A2 (fr) 2017-12-27
US20220184103A1 (en) 2022-06-16
EP3258965A4 (fr) 2018-08-29
US20180235986A1 (en) 2018-08-23
JP2023130496A (ja) 2023-09-20
JP2018506550A (ja) 2018-03-08
CN107249635A (zh) 2017-10-13
US20210137955A1 (en) 2021-05-13
WO2016133903A3 (fr) 2017-01-05

Similar Documents

Publication Publication Date Title
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3322448A4 (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
EP3377068A4 (fr) Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA41858A (fr) Polythérapie fgfr/pd-1 destinée au traitement du cancer
EP3488001A4 (fr) Traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA41123A (fr) Polythérapie pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA47408A (fr) Traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3375108A4 (fr) Traitement dewlan
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome